Mylan/Watson Emsam Label Discussions Await Marketing Partner
This article was originally published in The Pink Sheet Daily
Executive Summary
The joint venture Somerset is looking to sign a commercialization agreement with a company that has significant experience in the psychiatric market. The company would participate in labeling discussions for Emsam which is "approvable" at FDA.
You may also be interested in...
Emsam Deal Marks Bristol's Return To The Antidepressant Market
Under an agreement with the Mylan/Watson joint venture Somerset, Bristol will handle all marketing and detailing of the selegiline transdermal patch, which has been "approvable" at FDA since February 2004. Bristol left the antidepressant category in June when it stopped selling Serzone.
Emsam Deal Marks Bristol's Return To The Antidepressant Market
Under an agreement with the Mylan/Watson joint venture Somerset, Bristol will handle all marketing and detailing of the selegiline transdermal patch, which has been "approvable" at FDA since February 2004. Bristol left the antidepressant category in June when it stopped selling Serzone.